MétaCan
Menu
← Retour à la cohorte
Enregistrement W4414078742 · doi:10.1016/j.cont.2025.102021

97 - A Minimally Invasive Endo-Urethral Device for Stress Urinary Incontinence - a first human study

2025· article· en· W4414078742 sur OpenAlexaff
Enrico Finazzi Agrò, S. Secco, Roger R. Dmochowski, M Cecchi, Francesco Prata, Rocco Papalia, Giorgio Pomara, Francesca Manassero, C. Traversi, Tommaso Mazzocchi, Leonardo Marziale, Leonardo Ricotti, Guendalina Lucarini, Dean Elterman

Notice bibliographique

RevueContinence · 2025
Typearticle
Langueen
DomaineMedicine
ThématiquePelvic floor disorders treatments
Établissements canadiensUniversity of Toronto
Organismes subventionnairesnon disponible
Mots-clésUrinary incontinenceSiliconeUrethraProsthesis ImplantationUrinary system

Résumé

récupéré en direct d'OpenAlex

Hypothesis / aims of study Stress urinary incontinence (SUI) is a common condition, which affects patients’ quality of life, and is associated with significant implications for healthcare system resources. The most severe cases of SUI are treated with the implantation of artificial urinary sphincters [1] . The authors propose an innovative minimally invasive endo-urethral device (UroRelief) for the treatment of these patients. Study design, materials and methods The procedure utilizes an endo-urethral device positioned into the urethra through a standard cystoscopic procedure and local anaesthesia. The key element of the device is a silicone valve that replaces the function of the biological external urinary sphincter. The device valve is activated when the patient contracts the abdomen, resulting in the opening of the valve and the ability to void. The valve is incorporated in a Titanium frame that has the function of ensuring the proper anchoring and stability of the device. The shape memory behavior of Nitinol stents mounted on the device extremities allow easy insertion of the UroRelief valve, at the same time providing stability and device retention, once the valve is deployed. Results UroRelief has been tested on bench-test, ex-vivo tests on human cadavers, and in-vivo tests on 16 humans by means of two pilot studies. A first-in-human study was conducted involving 6 incontinent patients for 28 days to evaluate the device design concept with respect to initial clinical safety and device functionality [2] . Following investigator and patients’ feedback, the device was partly re-designed. The modified device has recently been tested by means of a second pilot study (10 patients) for 3 months in a multicenter clinical trial in Italy (3 centers) [3] . The second study results are presented below. Finally, a third pilot study is expected to start on September 2025. Interpretation of results In the second pilot study, device insertion was successfully performed in 8/10 patients. No issues with ease of insertion or removal were reported. Two patients were excluded from the study due to issues caused by deviations from the protocol's inclusion and exclusion criteria. Their exclusion was not related to any adverse events associated with the device or the procedure Patients experienced good to excellent continence restoration (i.e. urine losses were reduced between 59% and 99%), and good tolerability (i.e. no patients reported pain, seven patients reported slight discomfort, and one patient reported discomfort). The majority (8/10) of patients were discharged with the device located in situ, and they ended the study after 90 days with a properly working device. Some mild encrustations were observed in the Titanium frame and/or Nitinol stents without affecting performance or complicating the explant procedure. None of the patients required urgent intervention, and no UTIs were reported during the study. No serious adverse events were reported. Quality of life was considerably improved in the majority (8/10) of the cases with a reduction of urine loss up to 99%. Questionnaires demonstrated no chronic effects or no negative changes in the quality of life caused by the device insertion, no chronic discomfort or pain, no irritative effects, and no changes in urination frequency. Concluding message In conclusion this multicentre pilot study with the re-designed UroRelief device demonstrates its efficacy in addressing SUI, guaranteeing low invasiveness, and improving urinary continence in the majority of subjects. The improved design allowed for ease of insertion and maintenance of positioning without migration. The device has a promising future clinical application. Funding The study is supported by Relief a spinoff of Scuola Superiore Sant'Anna Clinical Trial Yes Registration Number NCT05449639 RCT No Subjects Human Ethics Committee Comitato Etico Campus Biomedico Roma Helsinki Yes Informed Consent Yes

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,005
score de la tête « metaresearch » (Gemma)0,003
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,012
Score d'incertitude au seuil0,039

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0050,003
Méta-épidémiologie (sens strict)0,0010,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0010,000
Études des sciences et des technologies0,0010,002
Communication savante0,0010,001
Science ouverte0,0010,001
Intégrité de la recherche0,0020,001
Charge utile insuffisante (le modèle a refusé de juger)0,0120,002

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,025
Tête enseignante GPT0,317
Écart entre enseignants0,292 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2025
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueContinence→Même sujetPelvic floor disorders treatments→Travaux en français237 207→